LONDON (Alliance News) - Circassia Pharmaceuticals PLC said Friday it has seen positive results from a two-year follow up of a phase IIb study of a house dust mite allergy product HDM-SPIRE.
Investigators reassessed patients' allergy symptoms two years after starting treatment with the product or a placebo.
The follow-up study enrolled a smaller number of subjects than the original treatment study, and was not able to deliver statistically significant results, Circassia said. However it was helpful for the design of future clinical studies.
The study showed that the treatment had lasting effects after two years without further injections, it said. As with previous studies, patients with more severe allergy symptoms showed a greater treatment effect compared to a placebo.
Circassia plans to begin a Phase IIb field study to confirm the efficacy of a short course, evaluate two courses of the product, and assess the safety of a higher dose. This study is on track to start in the fourth quarter of 2014.
Shares in Circassia were trading flat at 295.00 pence Friday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
